Why Jim Cramer Says Jamie Dimon's Throat Cancer Is Not a Reason to Sell J.P. Morgan (JPM) Stock

NEW YORK (TheStreet) -- TheStreet's Jim Cramer says the news that J.P. Morgan  (JPM) CEO Jamie Dimon has throat cancer is not a reason to sell the stock.

Dimon and the company have been straightforward in saying this is a beatable form of cancer. Cramer says those who are selling the stock should be aware of similar cases, such as Andrew Grove at Intel  (INTC), Robert Benmosche at AIG  (AIG) and Warren Buffett at Berkshire Hathaway  (BRK.B). Each of those figures said they had treatable forms of cancer, which "is not something you can just kind of blithely say," according to Cramer.

All three of those stocks went up not long after the news broke, as investors realized the truth about the curable cancers. Therefore, Cramer says he would not sell J.P. Morgan in the wake of the Dimon news.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team agrees, as it rates JPMORGAN CHASE & CO as a "buy" with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate JPMORGAN CHASE & CO (JPM) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."

If you liked this article you might like

Why Apple Pay Cash Won't Be a Venmo Killer: PayPal CEO

Fed Pares $4.5 Trillion Balance Sheet But Easy-Money Era Isn't Over

PayPal Has Billions in Cash and Is On the Prowl for Acquisitions

PayPal Hunting for a Big Deal?

Bank Stocks Move Higher as Fed Decides to Start Unwinding Balance Sheet